FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 06/01/2009 |
3. Issuer Name and Ticker or Trading Symbol
INOVIO BIOMEDICAL CORP [ INO ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Inovio Biomedical Corporation Common Stock(1) | 117,744 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Inovio Biomedical Corporation Stock Option(2)(3) | 12/16/2003 | 12/16/2013 | Inovio Biomedical Corporation Common Stock | 196,240 | $0.06 | D | |
Inovio Biomedical Corporation Stock Option(2)(3) | 12/01/2004 | 12/01/2014 | Inovio Biomedical Corporation Common Stock | 392,480 | $0.21 | D | |
Inovio Biomedical Corporation Stock Option(2)(3) | 12/17/2005 | 12/17/2015 | Inovio Biomedical Corporation Common Stock | 117,744 | $0.31 | D | |
Inovio Biomedical Corporation Stock Option(2)(3)(4) | 10/02/2006 | 10/02/2016 | Inovio Biomedical Corporation Common Stock | 29,436 | $2.3 | D | |
Inovio Biomedical Corporation Stock Option(2)(3)(5) | 01/18/2007 | 01/18/2017 | Inovio Biomedical Corporation Common Stock | 49,060 | $2.3 | D | |
Inovio Biomedical Corporation Stock Option(2)(3)(6) | 11/01/2007 | 11/01/2017 | Inovio Biomedical Corporation Common Stock | 14,718 | $2.3 | D | |
Inovio Biomedical Corporation Stock Option(2)(3)(7) | 09/12/2008 | 09/12/2018 | Inovio Biomedical Corporation Common Stock | 19,624 | $1.53 | D |
Explanation of Responses: |
1. Issued upon assumption of outstanding VGX Pharmaceutical Inc. common stock in conjunction with closing of the business combination transaction between VGX Pharmaceuticals and Inovio Biomedical Corporation on June 1, 2009. |
2. Issued upon assumption of outstanding VGX Pharmaceutical Inc. stock options in conjunction with closing of the business combination transaction between VGX Pharmaceuticals and Inovio Biomedical Corporation on June 1, 2009. |
3. The vesting schedule is based on the original grant. |
4. The first tranche of 9,812 shares vested on October 2, 2007, the second tranche of 9,812 shares vested on October 2, 2008, and the third tranche of 9,812 shares will vest October 2, 2009. |
5. The first tranche of 16,353 shares vested on January 18, 2008, the second tranche of 16,353 shares vested on January 18, 2009, and the third tranche of 16,353 shares will vest January 18, 2010. |
6. The first tranche of 4,906 shares vested on November 1, 2008, the second tranche of 4,906 shares will vest on November 1, 2009, and the third tranche of 4,906 shares will vest November 1, 2010. |
7. The first tranche of 6,541 shares will vest on September 12, 2009, the second tranche of 6,541 shares will vest on September 12, 2010, and the third tranche of 6,541 shares will vest September 12, 2011. |
/s/ Kevin Rassas | 06/01/2009 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |